Study of AZD3470 for blood cancers alone or with other drugs
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12–18 years old (depending on the specific group and your location).
- Have a diagnosis of classical Hodgkin's lymphoma or certain T-cell lymphomas that either came back or got worse after treatment.
- For Hodgkin's lymphoma groups: you must have tried at least 1–2 prior treatments, including specific drugs like brentuximab vedotin (BV) or an anti-PD1 drug.
- Have at least one tumor that can be seen on a scan (like a CT scan) and is at least 1.5 cm wide.
- Provide a sample of your tumor from a previous biopsy (and possibly a new biopsy during treatment).
- Be in generally good health with adequate organ and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.